Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62023TB0228(01)

    Case T-228/23: Order of the General Court of 7 February 2024 – Zaklady Farmaceutyczne Polpharma v Commission

    OJ C, C/2024/2623, 22.4.2024, ELI: http://data.europa.eu/eli/C/2024/2623/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    ELI: http://data.europa.eu/eli/C/2024/2623/oj

    European flag

    Official Journal
    of the European Union

    EN

    C series

    C/2024/2623

    22.4.2024

    Order of the General Court of 7 February 2024 – Zaklady Farmaceutyczne Polpharma v Commission

    (Case T-228/23)  (1)

    (Action for annulment - Medicinal products for human use - Marketing authorisation for the medicinal product Dimethyl fumarate Polpharma - dimethyl fumarate - Letter of the Commission drawing conclusions from a judgment of the Court of Justice - Measure not actionable - Inadmissibility - Hypothetical acts - Manifest inadmissibility)

    (C/2024/2623)

    Language of the case: English

    Parties

    Applicant: Zaklady Farmaceutyczne Polpharma S.A. (Starogard Gdański, Poland) (represented by: K. Roox, T. De Meese, J. Stuyck, M. Van Nieuwenborgh and C. Dumont, lawyers)

    Defendant: European Commission (represented by: C. Valero and E. Mathieu, acting as Agents)

    Re:

    By its action under Article 263 TFEU, the applicant seeks the annulment of the decision contained in the letter of the European Commission of 17 March 2023, with reference SANTE.DDG1.B.5/AL/mmc (2023) 2915860, concerning the interpretation and the consequences of the judgment of 16 March 2023, Commission and Others v Pharmaceutical Works Polpharma (C-438/21 P to C-440/21 P, EU:C:2023:213).

    Operative part of the order

    1.

    The action is dismissed as inadmissible in so far as it is directed against the decision contained in the letter of the European Commission of 17 March 2023, with reference SANTE.DDG1.B.5/AL/mmc (2023) 2915860, concerning the interpretation and consequences of the judgment of 16 March 2023, Commission and Others v Pharmaceutical Works Polpharma (C-438/21 P to C-440/21 P, EU:C:2023:213).

    2.

    The action is dismissed as manifestly inadmissible in so far as it is directed against any decisions taken after the decision contained in the letter of the European Commission of 17 March 2023, with reference SANTE.DDG1.B.5/AL/mmc (2023) 2915860, concerning the interpretation and the consequences of the judgment of 16 March 2023, Commission and Others v Pharmaceutical Works Polpharma (C-438/21 P to C-440/21 P, EU:C:2023:213), to the extent that they perpetuate and/or replace that decision, including any follow-up regulatory actions, in so far as they relate to the applicant.

    3.

    Zaklady Farmaceutyczne Polpharma S.A. shall bear its own costs and pay those incurred by the European Commission, including the costs relating to the interim proceedings.

    (1)   OJ C 235, 3.7.2023.

    ELI: http://data.europa.eu/eli/C/2024/2623/oj

    ISSN 1977-091X (electronic edition)

    Top